Results for maximal inhibition translation from English to Maltese

inhibition
(1.09-1.62)

inhibition.
inibizzjoni ta’ cyp3a4.

inhibition)
cyp3a)

inhibition and
darbtejn

(bcrp inhibition)
(impediment ta‟ bcrp)

cyp3a4 inhibition
inibizzjoni ta’ cyp3a4

(cyp3a inhibition)
(impediment ta’ cyp3a)

(p-gp inhibition)
(inibizzjoni ta’ p-gp)

(intestinal bcrp inhibition)
(inibizzjoni ta’ bcrp tal-musrana)

(cyp3a enzyme inhibition)
(inibizzjoni tal-enzima cyp3a)

2 maximal daily production capacity
2 kapaċità massima ta’ produzzjoni kuljum

the maximal dose is 10 mg daily.
id- doża massima hija 10 mg kuljum.

the maximal daily dose is 10 mg;
inizjali (2. 5 mg/ kuljum); id- doża massima ta ’ kuljum hi ta ’ 10 mg;

their maximal depth should be 130 cm.
il-fond massimu tagħhom irid ikun ta' 130ċm.

lng terminal capacity and maximal send-out capacity
kapaċità terminali u l-kapaċità massima tal-bgħit tal-lng

after a single dose of oromucosal midazolam, the consequence on the maximal clinical effect due to cyp3a4 inhibition will be minor while the duration of effect may be prolonged.
wara doża waħda ta’ midazolam mill-mukuża tal-ħalq, il- konsegwenza fuq l-effett kliniku massimu minħabba l-inibizzjoni ta’ cyp3a4 se tkun żgħira, filwaqt li t-tul ta’ żmien tal-effett jista’ jittawwal.

ruxolitinib resulted in maximal inhibition of stat3 phosphorylation 2 hours after dosing which returned to near baseline by 8 hours in both healthy subjects and mf patients, indicating no accumulation of either parent or active metabolites.
ruxolitinib wassal għal inibizzjoni massima tal- fosforilizzazzjoni ta’ stat3 sa sagħtejn wara li tingħata d-doża u li reġgħet lura għal kważi l-linja bażi sa 8 sigħat wara kemm f’pazjenti b’saħħithom kif ukoll f’pazjenti b’mf, u dan juri li ma kien hemm l-ebda akkumulazzjoni la tal-metaboliti ewlenin u lanqas ta’ dawk attivi.

maximal inhibition of metabolism of the co-administered protease inhibitor is generally achieved with ritonavir doses of 100 mg daily to 200 mg twice daily, and is dependent on the co-administered protease inhibitor.
l-impediment massimali tal-metaboliżmu ta’l-impeditur protejaż li jingħata ma’ ritonavir ġeneralment jintlaħaq b’dożi ta’ ritonavir ta’ minn 100 mg kuljum sa 200 mg darbtejn kuljum, u dan jiddependi fuq l-impeditur protejaż li jingħata ma’ ritonavir.

however, upon co-administration with cobicistat in genvoya, near maximal inhibition of p-gp by cobicistat is achieved leading to increased availability of tenofovir alafenamide with resulting exposures comparable to tenofovir alafenamide 25 mg administered alone.
madankollu, meta jingħata flimkien ma’ cobicistat fi genvoya, tinkiseb inibizzjoni ta’ p-gp minn cobicistat qrib il-massimu, u twassal għal żieda fid-disponibilità ta’ tenofovir alafenamide, bl-esponimenti li jirriżultaw li jkunu komparabbli għal tenofovir alafenamide 25 mg mogħti waħdu.

maximal plasma concentrations of imatinib in patients are 2-4 µmol/l, consequently an inhibition of cyp2d6 and/or cyp3a4/5-mediated metabolism of co-administered drugs is possible.
l-ogħla konċentrazzjonijiet fil-plażma ta’ imatinib fil-pazjenti jvarjaw minn 2-4 µmol/l, u għaldaqstant huwa possibbli li jinibixxi l-metaboliżmu permezz ta’ cyp2d6 u/ jew cyp3a4/5 ta’ mediċini li jingħataw fl-istess ħin miegħu.